Surgical De-escalation in Low-Risk Cervical Cancer

  • 📰 Medscape
  • ⏱ Reading Time:
  • 53 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 25%
  • Publisher: 55%

Law Law Headlines News

Law Law Latest News,Law Law Headlines

When it comes to preventing pelvic recurrence in low-risk cervicalcancer, simple hysterectomy is not inferior to radical hysterectomy, according to results from a phase 3, randomized, controlled trial. ASCO23

CHICAGO — When it comes to preventing pelvic recurrence in low-risk cervical cancer, simple hysterectomy is not inferior to radical hysterectomy, according to results from a phase 3, randomized, controlled trial.

Retrospective studies found that infiltration of the parametrium is quite rare in low-risk cases,"suggesting that less radical surgery may be a safe option associated with decreased morbidity – what we call surgical de-escalation," said Dr. Plante. There were no statistically significant differences in intraoperative complications or mortality between the groups.There were some differences between the groups with respect to surgery-related adverse events. Within 4 weeks of surgery, there was a greater incidence of any adverse event in the radical hysterectomy group , as well as greater incidences of urinary incontinence and urinary retention .

"Amongst those carefully selected tumors, radical hysterectomy can be converted to a simple hysterectomy, including minimally invasive. You still have to do nodes – that's an important thing to remember — but you can do this without loss of oncologic control. And importantly, with reduction in surgical complications, postop morbidity, specifically neurologic morbidity.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 386. in LAW

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows | CNNA drug used in people with the most common kind of breast cancer – early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER-) breast cancer – significantly reduced the risk of the cancer returning after treatment, according to a new study.
Source: cnni - 🏆 326. / 59 Read more »